In spite of advances in tuberculosis (TB) chemotherapy, TB is still airborne deadly disorder
as a major issue of health concern worldwide today. Extensive researches have been focused to develop
novel drug delivery systems to shorten the lengthy therapy approaches, prevention of relapses, reducing
dose-related toxicities and to rectify technologically related drawbacks of anti-tubercular drugs. Moreover,
the rapid emergence of drug resistance, poor patient compliance due to negative therapeutic outcomes
and intracellular survival of Mycobacterium highlighted to develop carrier with optimum effectiveness
of the anti-tubercular drugs. This could be achieved by targeting and concentrating the drug on
the infection reservoir of Mycobacterium. In this article, we briefly compiled the general aspects of
Mycobacterium pathogenesis, disease treatment along with progressive updates in novel drug delivery
carrier system to enhance therapeutic effects of drug and the high level of patient compliance. Recently
developed several vaccines might be shortly available as reported by WHO.